An updated analysis of ponatinib and blinatumomab combination in Ph+ acute lymphoblastic leukemia

MD Anderson Cancer Center shared a post on X:

“Dr. Hagop Kantarjian shares an updated analysis of the use of a ponatinib and blinatumomab combination in newly diagnosed patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia.”

Read further.
Source: MD Anderson Cancer Center/X

More posts featuring MD Anderson Cancer Center in OncoDaily.

The University of Texas MD Anderson Cancer Center is situated in Houston, Texas, and stands as a comprehensive cancer center. It is the largest cancer center in the United States. Affiliated with The University of Texas Health Science Center in Houston, MD Anderson Cancer Center has consistently secured the top spot among the best hospitals globally for cancer care and research.

Remarkably, it has held the #1 position in the U.S. News and World Report’s Best Hospitals rankings for cancer care for 19 out of the last 22 years. As of 2023, MD Anderson Cancer Center hosts the highest number of cancer clinical trials worldwide and has more NCI-funded projects than any other institute in the United States.

Hagop Kantarjian is the professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he also serves as the Samsung Distinguished Leukemia Chair in Cancer Medicine and Associate Vice President for Global Academic Programs. Dr. Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia, spanning over four decades.

His contributions include advancements in chronic myeloid leukemia treatment, such as tyrosine kinase inhibitors like imatinib, dasatinib, nilotinib, and bosutinib. Moreover, he has made discoveries in acute lymphocytic leukemia, myelodysplastic syndrome, and leukemias treatment, resulting in over 20 FDA-approved drugs.